



(11) (C) 1,338,078
(21) 557,550
(22) 1988/01/28
(45) 1996/02/20
(52) 530-15.06
C.L. CR. 167-129

BREVETS
—
MARQUES
DE COMMERCE
—
DROITS
D'AUTEUR
—
DESSINS
INDUSTRIELS
—
TOPOGRAPHIES
DE CIRCUITS
INTÉGRÉS

(51) Int.Cl. ⁶ A61K 39/00; A61K 39/39

(19) (CA) CANADIAN PATENT (12)

(54) Partial Cationization of Protein-Containing Antigens and
Method of Immunization and Desensitization

PATENTS
—
TRADE-MARKS

(72) Michael, Jacob Gabriel , U.S.A.

COPYRIGHT

INDUSTRIAL
DESIGN

(73) Same as inventor

INTEGRATED
CIRCUIT
TOPOGRAPHY

(30) (US) U.S.A. 07/009,234 1987/01/30
(US) U.S.A. CIP 07/147,063 1988/01/22

(57) 9 Claims

NO DRAWING

PARTIAL CATIONIZATION OF PROTEIN-CONTAINING
ANTIGENS AND METHOD OF IMMUNIZATION AND
DESENSITIZATION

This invention relates to a method of preparing a partially cationized protein-containing substance, such as an antigen, having increased antigenicity, to the product of this method, and to a method of enhancing immune response to a native antigen in a mammal.

10 The importance of the use of antigens in the prevention of infectious disease through immunization and in the treatment of allergies through desensitization is well known.

The basis of immunization is the exposure of the organism to be immunized to dead or weakened infectious agents (viruses, bacteria, toxins, etc.) or extracts thereof which contain a foreign, generally macromolecular substance which is capable of evoking an immune response. These substances are generally referred to as antigens. Likewise, allergic reactions can be lessened by desensitization, wherein such a substance is used to suppress the normal allergic response caused by foreign
20 substances, referred to as allergens.



1 Most antigens and allergens are either wholly or
partially composed of protein.

5 The action of antigens is thought to be dependent in
part on the antigen's affinity for certain binding sites
on cells of the living tissue affected by the antigen.
Such tissue may be blood, internal organs, skin, eyes,
etc. Interaction of the antigen to the binding site
stimulates the production of antibodies which in turn
10 defend the organism against infectious agents containing
the antigen.

 Because antigens are foreign substances, they can
have adverse side affects on the organism sought to be
15 immunized. This is most important in the treatment of
humans and livestock. It is therefore desirable to be
able to achieve an effective immunogenic response by
utilizing lower levels of the antigen. If antigenicity
can be increased, it necessarily follows that a smaller
20 dosage can be administered to achieve a given level of
immunization.

 One way to increase the antigenicity of a substance
is by using an adjuvant in conjunction with the antigen.
25 An adjuvant is a substance which augments the immunogenic
response by aiding the antigen's interaction with the
living tissue. Examples of adjuvants include alum salts
for human use. A problem which militates against the use
of adjuvants in in vivo immunization is the toxicity and
30 the side effects these compounds induce. Because of
this, adjuvants are generally disfavored for use in
humans or in any other organism where toxicity and/or
side effects are a concern. The elimination of the need
for adjuvant cooperation is therefore desirable.

1 Some foreign substances do not evoke an antigenic
response at all, or do so very poorly, when brought into
contact with living tissue. One theory is that such
substances lack the threshold amount of binding
5 capability or strength to cause such a response. It
would be advantageous to be able to convert such
substances from a non-antigenic form to an antigenic
form. This would allow vaccines to be produced which
could elicit an immunogenic response to a substance where
10 this was not previously possible.

 Immunization methods are normally carried out by
subcutaneous or intramuscular injection of the vaccine.
Oral intake of an antigen is not feasible in most
15 instances because it often causes suppression of rather
than increase in the immune response. Exceptions to this
general rule include live attenuated bacterial and viral
vaccines. Oral vaccines offer advantages such as lower
expense and ease in administration and packaging.
20 Therefore, it would be better to be able to administer
vaccines in oral form without loss in immunogenic effect.

 The chemical modification of antigens, particularly
protein-containing antigens, has been known for some time.
25 in fields of research, such as cell surface labelling,
see D. Danon, Use of Cationized Ferritin as a Label Of
Negative Charges On Cell Surfaces, J. Ultrastructure
Research, Vol. 38, pp. 500-510 (1972).

30 Prior methods of antigen cationization have taught
the complete cationization of the antigen molecule. Here
"complete cationization" is intended to mean that a given
substance has had all its groups amenable to cationiza-
tion so altered. Completely cationized antigens are
35 generally unsuitable for in vivo use due to their

excessive reactivity.

Nakamura et al. Jpn. J. Nephrol, 28(1), 37-44 (1986) disclose chemical cationization of bovine serum albumin.

Muckerheide et al., Fed. Proc., 45(3), abstract No. 55 (1986) disclose that cationized bovine serum albumin induces an antibody response.

Other background information is contained in the following references:

- 10 1. Barnes, J. and M. Venkatachalam, Enhancement of Glomerular Immune Complex Deposition by a Circulating Polycation. J. Exp. Med. 160:286 (1984).
2. Olte, T., S.P. Batstord, J.J. Mihatson, H. Takamija and A. Vogt, Quantitative Studies on in situ Immune Complex Glomerulonephritis in the Rat Induced by Planted Cationized Antigen. J. Exp. Med. 155:460-474 (1982).
3. Gallo, G., Caulen, T. Glaser, S.N. Emancipator and M.E. Lamm, Nephritogenicity and Differential Distribution of Glomerular Immune Complexes Related to Immunogen Charge. Lab. Invest. 48:460 (1983).
- 20 4. Schikwik, J., W.B. Van den Berg, L.B.A. van de Putte, L.A.B. Joosten & L. van den Bersselaar, Cationization or Catalase, Peroxidase, and Superoxide Dismutase: Effect or Improved Intrarticular Retention on Experimental Arthritis in Mice. J. Clin. Invest. 76:195 (1985).
5. Muckerheide, A., A.J. Pesce and J.G. Michael, Immunosuppressive Properties of a Peptic Fragment of BSA. J. Immunol. 119:1340 (1977).
6. Dosa, S., A.J. Pesce, D.J. Ford, A. Muckerheide and J.G. Michael, Immunological Properties as Peptic

1 Fragments of Bovine Serum Albumin. Immunol. 38:509
 (1979).

 7. Muckerheide, A., A.J. Pesce, and J.G. Michael,
5 Kinetics of Immunosuppression Induced by Peptic Fragments
 of Bovine Serum Albumin. Cell. Immunol. 50:340 (1980).

 8. Muckerheide, A., A.J. Pesce and J.G. Michael,
 Modulation of the IgE Immune Response to BSA by Fragments
10 of the Antigen. Cell. Immunol. 59:392 (1981).

 9. Border, W.A., H.J. Ward, E.S. Hamil and A.H.
 Cohen, Induction of Membranous Nephropathy in Rabbits by
 Administration of an Exogenous Cationic Antigen.
15 J. Clin. Invest. 69:451 (1982).

 10. Apple, R., B. Knauper, A. Pesce and J.G.
 Michael, Shared Determinants of Native and Denatured
 Bovine Serum Albumin are Recognized by Both B- and T-
20 Cells. Mol. Immunol. 21:901 (1984).

 11. Levine, B.B. and N.M. Vaz, Effect of
 Combinations of Inbred Strain Antigen and Antigen Dose on
 Immune Responsiveness and Reagin Production in the Mouse.
25 Int. Aron. Allergy Appl. Immunol. 39:156 (1970).

 12. Ferguson, T. A., T. Peters, Jr., R. Reed, A.J.
 Pesce and J.G. Michael, Immunoregulatory Properties of
 Antigenic Fragments from Bovine Serum Albumin. Cell.
30 Immunol. 73:1 (1983).

 13. Julius, M.H., E. Simpson and L.A. Herzenberg, A
 Rapid Method for the Isolation or Functional
 Thymus-derived Murine Lymphocytes. Eur. J. Immunol.
35 3:645 (1973).

1

14. Hoare, D.G. and D.E. Kosnland, A Method for the Quantitative Modification and Estimation of Carboxylic Acid Groups in Proteins. J. Biol. Chem. 242:2447 (1967).

5

15. Daron, D., L. Goldstein, Y. Markovsky and E. Skutelsky, Use of Cationized Ferritin as a Label or Negative Charges on Cell Surfaces. J. Ultrastructure Res. 38:500 (1972).

10

16. Warren, H.S., F.R. Vogel and L.A. Chedid, Current Status of Immunological Adjuvants. Ann. Rev. Immunol. 4:369 (1986).

15

17. Mills, Z.J. and E. Haber, The Effect on Antigenic Specificity of Changes in the Molecular Structure of Ribonuclease. J. Immunol. 91:536 (1963).

20

18. Heber-Katz, E., D. Hansburn and R.H. Schwartz, The Ia-molecule or the Antigen-presenting Cell Plays a Critical Role in Immune Responses Gene Regulation of T Cell Activation. J. Mol. Cell. Immunol. 1:3 (1983).

25

19. Buus, S., and O. Werdelin, Oligopeptide Antigens of the Angiotensin Lineage Compete for Presentation by Paraformaldehyde-treated Accessory Cell to T Cells. J. Immunol. 136:459 (1986).

30

20. Babbitt, B.P., P.M. Allen, G. Matsueda, E. Haber and E.R. Unanue, Binding of Immunogenic Peptides to Ia Histocompatibility Molecules. Nature (London) 317:359 (1985).

35

21. Buus, S., S. Color, C. Smith, J.H. Freed, C. Miles and H.M. Grey, Interaction Between a "Processed"

1 Ovalbumin Peptide and Ia Molecules. P.N.A.S. 83:2968
 (1986).

5 22. Larey, E.X., E. Margoliasn, F.W. Fitch and S.K.
 Pierce, Role of LBT4 and Ia in the Heteroolitic Response
 of T Cells to Cytochrome. J. Immunol. 186:3933 (1986).

10 23. A.N. Glazer, R.J. DeLange and D.S. Sigman,
 Chemical Modifications of Proteins. Lab. Techniques in
 Biochemistry and Mol. Biology, Vol. 4, Part I, p. 1-205.
 North-Holland (Am. Elsevier) (1976).

15 24. Alexander N. Glazer, The Chemical Modification
 of Proteins by Group-Specific and Site Specific Reagents.
 1-103. In: The Proteins, 3rd ed. Vol. II Acad. Press,
 N.Y. (1976).

 Where cited herein, these publications are referred
 to by their numbers in the above list.

20

 There has heretofore been no recognition in the
 prior art that cationized antigens can be used in in vivo
 treatment and prevention of disease by use as vaccines or
 desensitization agents. Furthermore, the prior art has
25 not recognized that partially cationized antigens can be
 used for this purpose. Indeed, it has been reported that
 completely cationized antigenoproteins do not exhibit
 altered immunological properties (9).

30 It is an object of the invention to provide a
 partially cationized antigenic protein-containing
 substance, and a method for the preparation thereof,
 which can be administered orally, and which does not
 require an adjuvant.

35

SUMMARY OF THE INVENTION

As used herein, "protein-containing substance" includes all proteins, as well as substances whose molecular makeup is in some part proteinaceous, such as lipoproteins and proteosaccharides. These may be substances which do or do not have antigenic properties in their native forms. More specific examples of said substances include, without limitation, bovine serum albumin (BSA), hen egg albumin (OVA), bovine gammaglobulin (BGG), ferritin, bacterial endotoxin, viral proteins, diphtheria toxin and tetanus toxoid, and killed microorganisms, including bacteria and viruses and protein-containing products thereof.

As used herein, cationization means the conversion or substitution of functional groups on the protein portion of the protein-containing substance whereby the substance is rendered relatively more cationic. Such functional groups are normally anionic within a physiologic pH range and are converted to or substituted for a cationic or nonionic moiety. An example of such a cationization is the reaction whereby anionic side chain carboxyl groups are substituted with polycationic aminoethylamide groups.

As used herein, the unreacted or "native" form of the protein-containing substance is indicated by a prefix "n" and the cationized form is indicated by a prefix "c". For example, bovine serum albumin (BSA) may be expressed as either "nBSA" as the native form, or "cBSA" as the cationized form.

According to one aspect of the present invention there is provided a protein-containing substance, for use as a vaccine or a desensitization agent in the treatment or prevention of

disease, said substance being partially cationized through the attachment of at least one agent selected from primary amines, secondary amines and tertiary amines, wherein

a) said partially cationized protein-containing substance has an isoelectric point, as measured by isoelectric focusing in a polyacrylamide gel, less than 9.5; and

b) the immunological response of an animal to the partially cationized protein-containing substance is greater than to the unmodified, native protein-containing substance.

10 According to a further aspect of the present invention there is provided the use of a partially cationized antigen in the manufacture of a preparation for enhancing the immune response of an animal to an unmodified, protein-containing antigen, said antigen being partially cationized through use of an agent selected from the primary amines, secondary amines and tertiary amines so that

a) the isoelectric point of the modified antigen is less than 9.5; and

20 b) the partially cationized antigen induces in said animal a stronger immunological response than the unmodified antigen.

 According to the invention there is provided a partially cationized antigenic protein-containing substance having increased antigenicity as compared to the same native protein-containing substance, the partially cationized substance having an isoelectric point less than 9.5 and preferably from 6.5 to 9.5, determined by isoelectric focusing as hereinafter described.

The invention also provides such a partially cationized protein-containing substance for immunizing a mammal. Administration can be effected orally or parenterally, with or without an adjuvant.

A preferred method of partial cationization involves use of a reagent comprising at least one carbodiimide and at least one amine. Control of the degree of cationization is effected by varying the pH, time parameters and concentration of the reactants. The reaction may be halted or quenched
10 readily at a desired degree of partial cationization, in a manner known in the art. By way of non-limiting example, BSA reaction with a carbodiimide and amine mixture may be quenched after substitution of about 20 new amino groups in place of anionic carboxyl groups. A fully cationized BSA would contain about 80 new amino groups.

1

In general, an addition or substitution of from about 20% to about 60% of the theoretical maximum possible number of amino groups will result in an isoelectric point ranging between about 6.5 and 9.5 as determined by isoelectric focusing.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

10 The protein-containing substance (PCS) can be cationized by several methods known in the art (15, 9). The preferred method is the reaction of ethylenediamine/1-ethyl-3-(3-dimethyl amino propyl)-carbodiimide (EDC) with the PCS. This particular reaction involves the
15 activation of the carboxyl groups of a protein with carbodiimide and the subsequent reaction of the activated carboxyl with a nucleophile of the general type +R-NH₂ to obtain the primary amine type derivatives. Considerable versatility can be achieved since both the chemical
20 nature of the modification, i.e. introduction of primary, secondary or tertiary amine groups and the degree of modification of the protein carboxyls can be varied by proper choice of reagents, reaction time and pH of the coupling reaction.

25

 The cationization methods suitable for use in the present invention are those which effect cationization under mild reaction conditions. As used herein mild reaction conditions are those under which the molecular
30 character (e.g. 1°, 2° and 3° structure) of the subject PCS is not substantially altered so as to adversely affect its antigenic pH immunogenic character. These conditions can be most generally described as under relatively low temperature and low ionic strength as well
35 as neither very acidic (e.g. below pH 4) nor very basic

1 (e.g. above pH 8) nor presenting a very oxidative or
reductive environment.

5 The pH of the EDC reaction is generally maintained
in the range of from about 4.5 to about 6.8. More rapid
substitution of carboxyl groups in the EDC reaction
occurs at the lower pH levels within this general range.
For example, BSA cationized at pH 6.0 for 30 minutes
migrated during electrophoresis the same distance as BSA
10 cationized at pH 4.75 for 15 minutes (i.e., 0.7cm).

Reaction time is determined by the concentration of
the reactants and by the degree of cationization desired.
The preferred reaction time is in the range of from about
15 5 minutes to no more than two hours.

The reaction is maintained within the general range
of from about 4° C to about 37° C and is generally
maintained at about 25° C.

20

Each known method of cationization may be halted or
quenched according to several methods known in the art.
The EDC reaction is quenched with a buffer, preferably an
acetate buffer, which halts the reaction. Concentration
25 of the acetate buffer is about 4M.

Cationization can be verified and quantified using
known gel electrophoresis as hereinafter described, and
isoelectric focusing techniques known in the art. (14)
30 Ninhydrin reagent can also be used to determine the
number of amino groups substituted in a protein molecule
as shown hereinafter.

It is preferred that the protein-containing
35 substance be cationized to an extent whereby it exhibits

1 increased antigenic character such as an increased
immunogenic character or an increased allergic response
suppressing character. Such increases may be determined
5 by methods known in the art such as those described
below. Although not a limitation to the scope of the
applicability of the invention, for most types of PCS,
this will be at a point where the isoelectric point falls
within a range of from about 6.5 to about 9.5.

10 Also as a nonlimiting guide, most PCS types which
are modified to such an extent so as to increase their
antigenic character will generally have from about 20% to
about 60% of the maximum possible number of those anionic
15 groups amenable to modification under "mild" conditions
while that PCS is in its native state, so modified. As
used herein "modified" is intended to mean any type of
chemical modification which causes cationization of the
PCS.

20 Although most of the PCS types modified according to
the inventive method fall into the above-described
isoelectric point range, it is within the skill in the
art to determine and adjust the degree of partial
cationization which increases the antigenic character for
25 all PCS types including those PCS types, in native or
cationized form, whose isoelectric points may fall
outside this range.

The following Examples exhibit the inventive method
30 as practiced on several antigens. Variations of the
parameters and methodology for optimization of the method
for any specific PCS is within the known art.

1

Example 1

5

Bovine Serum albumin (nBSA), five times crystallized, was cationized according to the general procedure described by Border (9).

10

Five grams of nBSA was dissolved in distilled water to a volume of 25 ml and admixed with a solution of 67 ml ethylene diamine in 500 ml distilled water. The pH of this solution was adjusted to about 4.75 with 6N HCl. To this was added 1.8 grams of 1-ethyl -3-(3 dimethyl amino propyl)-carbodiimide.

15

The reaction was permitted to react for varying periods of time with constant stirring, while the temperature was maintained at about 25° C and the pH was held constant. After quenching with 4M acetate buffer mixture, the reaction was subjected to multiple dialysis treatments against distilled water and lyophilized. It was then passed through a column of Sephadex G-25 and lyophilized again before use.

20

EXAMPLE 2

25

The method of Example 1 with the exception that the pH of the reaction was adjusted to about 6.0 with 6N HCl and the reaction was permitted to react for about 1 hour.

EXAMPLE 3

30

The method of Example 1 with the exception that the PCS may be native bacterial endotoxin instead of nBSA.

35

1

Example 4

The method of Example 1 with the exception that the PCS used was native tetanus toxoid instead of nBSA (purchased from Lederle Laboratories, Pearl River, NY).

5

Example 5

The method of Example 2 with the exception that the PCS used was native hen egg albumin (OVA) instead of nBSA.

10

Example 6

15

The method of Example 1 with the exception that the PCS used was ferritin (purchased from Sigma Chemical Co., St. Louis, MO), samples of which were cationized for 5 minutes, 15 minutes and 30 minutes.

20

Example 7

The method of Example 1 with the exception that the PCS used was heat killed E.coli bacteria.

25

Example 8

The method of Example 1 with the exception that the PCS used was bovine gamma globulin (BGG), purchased from Sigma Chemical Co., St. Louis, MO.

30

Example 9

The method of Example 1 with the exception that fluorescein isothiocyanate (FITC), a small

35

1 non-immunogenic molecule, was conjugated either to an
nBSA carrier or to a cBSA carrier (as prepared in Example
1). These conjugates were used as the PCS. The
fluorescein isothiocyanate-BSA conjugation method is as
5 follows:

FITC is used in 0.5 mg concentration per mg of
protein. FITC is added to BSA solution and the pH is
adjusted to about 8.4 with borate buffer. The
10 conjugation is allowed to proceed for about 1 hour with
continuous mechanical stirring at slow speed.

The suspension is dialyzed in a cold room with
frequent changes of saline adjusted to a pH of about 7.8
15 with borate buffer. The dialysis requires several days
and is complete when the dialyzate is virtually free of
yellow-green color under ultraviolet light. The
conjugate is clarified by centrifugation.

20 Other hapten-carrier conjugations may require more
complex chemical reactions to achieve covalent bonding
between the reacting molecules.

Cationization Assay: Agrose Gel Electrophoresis

25

Materials:

1) Corning® Electrophoresis Agarose Universal Gel
Film (1% Agarose, 5% sucrose, 0.035% EDTA, in 0.065M
30 barbital buffer, pH 8.6);

2) Corning® Universal PHAB Buffer (Sodium barbital
17.7g, barbital 2.6g, sodium chloride 1.0g, disodium EDTA
0.7g, and sucrose octaacetate) Reconstituted with
35 distilled water to 0.05M buffer with 0.035% EDTA, pH 8.6.

- 3) Corning [®] Amido Black 10B Stain

NOTE: Above purchased from Fisher Scientific.

- 4) Corning [®] Cassette Electrophoresis Cell with
Corning Power Supply.

METHODS:

- 1) 1.0 μ l of sample at a concentration of 30 mg/ml
is loaded onto gel into each well. (For sample of lesser
concentration, 1 μ l of sample is loaded and allowed to dry
10 between applications until appropriate concentration is
reached).
- 2) 95 μ l buffer is added to each side of cell.
- 3) Gel is placed on electrophoresis unit and run for
appropriate time period. (For cBSA - time period is 40 minutes;
nBSA is run as a control).
- 4) Gel is removed from electrophoresis unit and
placed in amido black stain for 15 minutes. Gel is destained in
5% acetic acid for 20 seconds.
- 5) Gel is allowed to dry.
- 20 6) Gel is destained again in 5% acetic acid until
good contrast is seen between band and background.
- 7) Gel is rinsed in 2 separate distilled H₂O baths.
- 8) Gel is again allowed to dry.

1

Samples may be subjected to isoelectric focusing to determine the isoelectric point (pI) value of the particular cationized product, by a conventional procedure described in the prior art.

5

Results:

10

Chemical Properties and Electrophoresis

The cationization procedure results in the substitution of anionic side chain carboxyl groups by polycationic aminoethylamide groups (14, 15). The products are readily soluble in water and show a single band on gel electrophoresis in the presence of sodium dodecyl sulfate, with or without a reducing agent such as mercaptoethanol. The band migrates more rapidly toward the cathode than the native BSA monomer. Passage through Sephadex G 200 shows a single peak which appears slightly before the nBSA peak.

20

Electrophoresis on agarose gel (Table 1) shows that the two hour reaction time produces a molecule which appears to have attained a maximum positive charge in the case of cBSA since preparations which are permitted to react for a longer period of time do not exhibit increased migration toward the cathode.

25

The following results were obtained using the above outlined agarose gel technique:

30

35

1

Electrophoresis Results

5

10

15

<u>Reaction Time</u>	<u>Distance Migrated Toward Cathode (cm)</u>		
	<u>cBSA</u>	<u>cFerritin</u>	<u>cOVA</u>
15 min.	0.7	1.0	3.0
30 min.	1.0	1.3	4.0
60 min.	1.6	1.7	5.0
90 min.	1.9	N/T	5.3
120 min..	2.1	N/T	5.5
150 min.	2.1	N/T	N/T
180 min.	2.1	N/T	N/T

N/T = Not Tested

20

The products were determined to have an isoelectric point greater than 6.5 and up to about 9.5. The isoelectric point is used as one of the measures to determine the degree to which a given PCS has been cationized.

Amino Group Determination Using Ninhydrin Reagent

25

30

The number of amino groups substituted in a protein molecule by cationization can be determined by means of ninhydrin reagent. Ninhydrin reagent, purchased from Sigma Chemical Co., was used to prepare a curve with increasing concentrations of glycine, which served as a standard. An experimental procedure with BSA was as follows:

35

Ninhydrin reagent was added to a cBSA dilution and to nBSA (control), and the mixtures were heated at 80°C for 20 minutes, at which point the color of each mixture

1 was read on a spectrophotometer at 550. A BSA sample,
cationized for 15 minutes with ethylene diamine/EDC and
quenched with an acetate buffer, showed a gain of 20 new
amino groups over the native BSA control. Fully
5 cationized BSA should contain about 80 new amino groups.
The isoelectric point of the BSA sample cationized for 15
minutes was 8.0. It is thus possible to determine quanti-
tatively the number of amino group substitutions on a
molecule of a protein-containing substance.

10

Such a determination is useful in expressing the
degree to which a protein-containing substance has been
cationized. The degree of cationization may thus be
expressed as a percentage of those anionic groups amen-
15 able to substitution under relatively mild conditions
(i.e. the reaction conditions of the inventive cationiza-
tion method disclosed herein) while the protein-con-
taining substance is in its native state, which are
substituted to effect cationization. This percentage,
20 though not all inclusive, is usually in the range of from
about 20% to about 60%.

Immunogenicity and Desensitization Studies.

25 Mice: BDF₁ and BALB/c mice. 6-8 weeks of age, were
purchased from the Jackson Laboratory, Bar Harbor, ME.

Adjuvants: Complete and incomplete Freund's Adjuvant
(IFA) and bacterial lipopolysaccharide were purchased
30 from Difco Laboratories, Detroit MI. Aluminum hydroxide
gel was prepared in our laboratory according to the
method of Levine and Vaz (11) or was in the form of
commercial Maalox* (Rorer Inc., Fort Washington, PA).

35

* Trade-mark

Antibody Assays: A quantitative ELISA technique was used as previously described (12). Standard curves were run each time an assay was performed, using known amounts of antibody raised against either native or cationized BSA. The sera were then assayed on antigen-coated ELISA plates. The coatings used on plates varied in some tests and these variations are described in the Tables below, where applicable.

T cell proliferation assays: BDF₁ mice were injected in the hind footpads and tail base with 100 µg native or cationized antigen emulsified in Incomplete Freud's Adjuvant. The inguinal and popliteal lymph nodes were removed 10 days later and the subsequent cell suspension was passed over a nylon wool column as has been described (13). The nylon wool non-adherent cells were then resuspended in complete RPMI 1640 medium containing 10% horse serum, 1mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM glutamine, 5×10^{-5} M 2-mercaptoethanol, 25 mM HEPES and 5 µg/ml gentamycin, and plated in 96 well flat bottom plates (Costar, Cambridge, MA) at 5×10^{-5} cells/well. Native or cationized antigen were added at various concentrations in serum-free complete RPMI 1640 to triplicate wells. Serum-free medium served as a control. Cells were incubated at a final volume of 200 µl at 37°C with 5% CO₂ for 72 hours at which time 1 µCi ³H-thymidine was added to each well. Cells were harvested 20 hours later using a Skatron harvester and radioactivity was determined by liquid scintillation spectrophotometry.

The following results were obtained with cBSA cOVA cFerritin, cE.Coli bacteria, cTetanus Toxoid, cBGG and FITC-

cBSA conjugate, in immunogenicity and desensitization studies comparing their antigenicity to that of their native forms.

Table A

Immunization	Anti BSA Antibodies ($\mu\text{g/ml}$)		
	9d	14d	21d
50 μg n BSA, i.v. injection 5 times	58	28	0
10 50 μg cBSA, i.v. injection 5 times	393	450	425

cBSA prepared as in Example 1.

Tested on BSA plate.

Table A shows that cBSA is immunogenic when injected
into mice.

Table B

EFFECT OF CATIONIZATION ON IMMUNOGENICITY
OF BOVINE SERUM ALBUMIN

Time of Cationization	Immunogenicity- Antigen Specie	Relative
		$\mu\text{g/ml}$ Antibody
None	nBSA	350
30 15 min.	cBSA	1220
30 min.	cBSA	1450
60 min.	cBSA	1135
120 min.	cBSA	110

Anti BSA response μg antbs/ml at 14d).

Cationization was conducted at a pH of 4.75 and at a temperature of 25°C .

Table B shows that the length of time of protein cationization controls its immunogenicity. Cationization

optimizes immune responsiveness. However, if cationization is excessive, immunogenicity is sharply reduced, if not totally eliminated. Administration was intraperitoneal (i.p.) with alum adjuvant (1 mg/dose).

Table C

**EFFECT OF CATIONIZATION ON ANTIGEN REACTIVITY
(BOVINE SERUM ALBUMIN)**

<u>Time of Cationization</u>	<u>Antigen Specie</u>	<u>Relative Antigen Activity</u>
None	nBSA	++
15 min.	cBSA	+++
30 min.	cBSA	++++
60 min.	cBSA	+++
120 min.	cBSA	-

BSA primed T lymphocytes responsiveness to antigen

Table C shows that too extensive cationization of BSA creates a molecule incapable of stimulating BSA primed T lymphocytes.

Cationization for a time up to 60 minutes greatly enhances the ability of BSA to stimulate lymphocyte proliferation, but excessive cationization creates a non-immunogenic or poorly immunogenic molecule.

Table D

Effect of in vivo pretreatment
with soluble nBSA or cBSA
on the IgG antibody response to
either antigen

10	<u>Group</u>	PRETREATMENT d -9,8,7 (intravenous)	IMMUNIZATION (intraperitoneal)	% Enhancement OR SUPPRESSION ¹		
				10d	14d	21d
	A	100 µg nBSA	100 µg nBSA in alum	-18	-26	-51
	B	100 µg nBSA	100 µg nBSA in IFA ²	-95	-94	-92
	C	100 µg nBSA	100 µg cBSA in IFA	-84	-87	-91
	D	100 µg cBSA	100 µg cBSA in alum	2200	6055	400
20	E	100 µg cBSA	100 µg cBSA in IFA	98	113	28
	F	50 µg cBSA	100 µg cBSA in IFA	184	241	42

¹ Compared to control groups immunized with nBSA or cBSA and pretreated with physiological saline. Suppression indicated by negative value.

30 ² Incomplete Freund's Adjuvant

d = day

cBSA was prepared as in Example 1.

Table D shows that cBSA evoked greater immune response following initial pretreatment with cBSA whereas nBSA actually suppressed the production of anti BSA antibodies.

Table E

Effect of in vivo pretreatment
with doses of soluble cBSA
on the immune response (IgG)
to either antigen

10	Group	PRETREATMENT d -9,8,7 (intravenous)	IMMUNIZATION	% ENHANCEMENT OR SUPPRESSION ¹	
				10d	21d
	A	25 µg cBSA	100 µg nBSA	259 ²	413
	B	25 µg cBSA	100 µg cBSA	497	274
	C	10 µg cBSA	100 µg nBSA	867	2818
	D	10 µg cBSA	100 µg cBSA	566	683
20	E	1 µg cBSA	100 µg nBSA	230	866
	F	1 µg cBSA	100 µg cBSA	1321	1018
	G	25 µg nBSA	100 µg nBSA	-85	-27
	H	25 µg nBSA	100 µg cBSA	-22	NS ³
	I	10 µg nBSA	100 µg nBSA	-87	NS ³
30	J	10 µg nBSA	100 µg cBSA	NS	NS
	K	1 µg nBSA	100 µg nBSA	NS	NS
	L	1 µg nBSA	100 µg cBSA	NS	NS

¹ Immunizations were given intraperitoneally using 1 mg alum as adjuvant.

² Compared to control groups immunized with nBSA or cBSA and pretreated with physiological saline. Suppression indicated by negative value.

³ NS = not significant (less than 5% change).

Table E shows results of a more detailed study of the immune response to BSA obtained with small quantities (1-25 mg) of the cationized BSA and the resulting immune response, both in terms of increase in enhancement and the longevity of the increase.

Table FEFFECT OF ORAL ADMINISTRATION OF ANTIGEN
ON IgG RESPONSE

	Feeding (3 x 20 mg)	Immunization (100 µg) in alum	Anti BSA Response - IgG (µg/ml)		
			10d	14d	24d
10	-	BSA	900	812	240
	-	cBSA	1024	2076	3050
	BSA	BSA	87	58	57
	cBSA	BSA	2700	1074	875
	BSA	cBSA	250	287	675
	cBSA	cBSA	3700	6300	6300
20					

Tested on BSA plate

Table GEFFECT OF ORAL ADMINISTRATION OF ANTIGEN
ON IgE RESPONSE

	Feeding (3 x 20 mg)	Immunization (100 µg) in alum	Anti BSA Response - IgE PCA titer		
			10d	14d	24d
10	-	BSA	40	82	80
	-	cBSA	80	160	160
	BSA	BSA	20	20	40
	BSA	BSA	20	20	20
	BSA	cBSA	10	10	10
20	cBSA	cBSA	20	20	20

Tables F and G show the effect of oral administration of the cationized and native form of the antigen. Table F records the increase in anti-BSA IgG levels resulting from cBSA immunization, while Table G shows that cBSA suppresses anti-BSA IgE levels.

Table HEFFECT OF ORALLY ADMINISTERED cOVA
ON IMMUNE RESPONSE TO nOVA AND cOVA

	<u>Feeding with 20 mg Antigen</u>	<u>Intraperitoneal Immunization with 0.1 μg Antigen in 1 μg Alum</u>	<u>Immune Response Anti OVA at 14d (μg/ml)</u>
10	None	nOVA	140
	None	cOVA	765
	nOVA	nOVA	35
	nOVA	cOVA	180
	cOVA	nOVA	1320
20	cOVA	cOVA	2250

OVA cationized for 1 hour as described in Example 5.

Table H shows that feeding with nOVA suppresses immune response to OVA. In contrast, feeding (oral administration) with cOVA enhances greatly the immune response to both nOVA and cOVA.

Table IIMMUNE RESPONSIVENESS TO cOVA
AND nOVA in BDF₁ MICE

	Antigen Administered <u>i.p. with 1 mg Alum</u>	Response Days After Immunization (μ g/ml Anti-OVA Antibodies)		
		<u>9d</u>	<u>14d</u>	<u>21d</u>
10	0.1 μ g nOVA	80	120	120
	1.0 μ g nOVA	450	840	660
	10 μ g nOVA	1250	1420	1300
	0.1 μ g cOVA	425	976	770
	1.0 μ g cOVA	1300	2010	1660
20	10 μ g cOVA	1500	2350	3200

OVA cationized as described in Example 5.

Table I shows cOVA is far more immunogenic than nOVA most notably at lower doses of antigenic challenge.

Table J

**EFFECT OF INTRAPERITONEALLY ADMINISTERED
CATIONIZED FERRITIN IN BDF₁ MICE**

5

		<u>Percent enhancement c Ferritin over n Ferritin (control)</u>		
10	<u>Bled at days</u>	<u>5 min. cF</u>	<u>15 min. cF</u>	<u>30 min. cF</u>
	9	169	97	217
	15	134	101	490
	21	122	123	241
15	35	195	206	457

Cationized Ferritin, cF, was produced as described in Example 6, and administered i.p. to BDF₁ mice. Antibody levels were determined from time-interval bleeds measured by ELISA on plates coated with native ferritin.

Table J shows a substantial increase in immunogenicity of partially cationized ferritin.

25

30

35

Table K**EFFECT OF I.p. ADMINISTERED
CATIONIZED E coli BACTERIA IN BDF₁ MICE****Percent enhancement over controls**

No. of bacteria injected	<u>Percent enhancement over controls</u>		
	<u>10 days</u>	<u>20 days</u>	<u>30 days</u>
1 x 10 ⁶	160	210	180
5 x 10 ⁶	220	450	650
1 x 10 ⁷	260	500	460
5 x 10 ⁷	320	800	650

Heat killed E. coli bacteria were cationized as in Example 7 and washed 3 times with saline and injected i.p. into mice, and the mice were later bled. Antibody concentration was determined by ELISA in which plastic plates were coated with untreated bacteria. Antibacterial antibody titers in mice immunized with untreated bacteria served as controls and were compared with antibody titers from mice immunized with partially cationized bacteria.

Table K shows a substantial increase in immunogenicity of partially cationized bacteria.

Table L**EFFECT OF I.p. ADMINISTERED
CATIONIZED TETANUS TOXOID IN BDF₁ MICE**

5

<u>Immunization</u> <u>i.p. with</u> <u>1 mg alum</u>	<u>Anti-tetanus antibody</u> <u>Percent enhancement cTT</u> <u>over nTT (control)</u>		
	<u>14 days</u>	<u>28 days</u>	<u>35 days</u>
1 ug cTT	220	300	320
10 ug cTT	325	560	720
100 ug cTT	280	450	660

15

Tetanus Toxoid was cationized as described in Example 4.

20

Animals were bled at various time intervals and antibody levels were determined by ELISA on native TT.

Table L shows that partial cationization increases the immunogenicity of tetanus toxoid.

25

30

35

Table MEFFECT OF I.p. ADMINISTERED
CATIONIZED BGG IN BDF₁ MICEAnti-BGG antibodies
µg/ml

10	<u>Immunization</u>			
	<u>i.p. with</u> <u>1 mg alum</u>	<u>9 days</u>	<u>14 days</u>	<u>21 days</u>
<u>nBGG</u>				
	1 µg	55	80	60
	10 µg	110	400	800
20	50 µg	350	850	1000
	100 µg	320	1200	1200
<u>cBGG</u>				
	1 µg	110	180	180
	10 µg	450	1200	1600
30	50 µg	1200	2500	2500
	100 µg	850	2100	2600

Bovine Gamma Globulin (BGG) was cationized as described in Example 8.

Animals were bled at various time intervals and antibody levels were measured by ELISA. Column purified anti-BGG antibodies were used as standards. Each group comprised 5 mice, and the entire experiment was repeated twice.

Table M demonstrates that partial cationization greatly increases the immunogenicity of Bovine Gamma Globulin.

Table N

**EFFECT OF FITC CONJUGATED TO cBSA
IN BDF₁ MICE**

5

	<u>Bled</u> <u>at days</u>	percent enhancement FITC-cBSA over <u>FITC-nBSA (control)</u>
10	10	240
	15	280
	22	330
	30	180
	37	160

15

FITC-BSA conjugates were prepared as described in Example 9.

20 Immune response was determined by measuring antibodies produced against FITC-nBSA or FITC-cBSA in mice on ELISA plates coated with FITC-KLH conjugate.

25 Table N shows that a small non-immunogenic molecule, a hapten such as FITC, becomes highly immunogenic when conjugated to a partially cationized protein (cBSA).

30

35

1 The above data establish that the method of
immunizing a mammal or suppressing allergic response in a
mammal in accordance with the invention includes
administering an effective amount of a partially
5 cationized antigenic protein having an isoelectric point
ranging from about 6.5 to about 9.5, the administration
being either oral or parenteral, and with or without an
adjuvant. A method of enhancing immune response to a
native antigen in a mammal comprises administering
10 parenterally to a mammal an effective amount of that
antigen which has been partially cationized such that its
isoelectric point ranges from about 6.5 to about 9.5, and
thereafter administering parenterally to the mammal an
amount of that native antigen sufficient to evoke an
15 immune response.

Although the invention is in no way limited by any
theory as to why beneficial results are achieved, it is
postulated that cationized proteins may be more
20 immunogenic for the following reasons:

1. Increased affinity for antigen presenting
cells (APC).
- 25 2. Alterations in the antigen processing by
the APC.
3. More efficient recognition by T helper
cells.
- 30 4. Greater affinity for self recognition
antigens (Ia).
5. Greater affinity for T cell receptors.

6. Activation of a new type of T helper cells with more efficient recognition of the antigen.

The above examples are for illustrative purposes only.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A protein-containing substance, for use as a vaccine or a desensitization agent in the treatment or prevention of disease, said substance being partially cationized through the attachment of at least one agent selected from primary amines, secondary amines and tertiary amines, wherein

a) said partially cationized protein-containing substance has an isoelectric point, as measured by isoelectric focusing in a polyacrylamide gel, less than 9.5; and

b) the immunological response of an animal to the partially cationized protein-containing substance is greater than to the unmodified, native protein-containing substance.

2. The partially cationized protein-containing substance according to claim 1, having an isoelectric point in the range from 6.5 to 9.5.

3. The partially cationized protein-containing substance according to claim 1 or claim 2 wherein the unmodified protein-containing substance is selected from bovine serum albumin, hen egg albumin, bovine gamma globulin, ferritin, bacterial endotoxin, viral proteins, tetanus toxoid, diphtheria toxin, and killed microorganisms and protein-containing products thereof.

4. The partially cationized protein-containing substance according to claim 1 or 2, being conjugated with a hapten, and wherein the immunological response of an animal to the hapten,

conjugated to the partially cationized protein-containing substance, is greater than to the hapten, conjugated to the unmodified native protein-containing substance.

5. The use of a partially cationized antigen in the manufacture of a preparation for enhancing the immune response of an animal to an unmodified, protein-containing antigen, said antigen being partially cationized through use of an agent selected from the primary amines, secondary amines and tertiary amines so that

a) the isoelectric point of the modified antigen is less than 9.5, and

b) the partially cationized antigen induces in said animal a stronger immunological response than the unmodified antigen.

6. The use of a partially cationized antigen according to claim 5, wherein the partially cationized antigen has an isoelectric point in the range 6.5 to 9.5.

7. The use of a partially cationized antigen according to claim 5 or claim 6, wherein the unmodified antigen is selected from bovine serum albumin, hen egg albumin, bovine gamma globulin, ferritin, bacterial endotoxin, viral proteins, tetanus toxoid, diphtheria toxin, and killed microorganisms and protein-containing products thereof.

8. The use of a partially cationized antigen according to

claim 5 or 6, wherein the partially cationized antigen is conjugated with a hapten, and wherein the level of antibodies produced by the animal to the conjugated hapten/partially cationized antigen is greater than to the hapten conjugated with the unmodified antigen.

9. The use of a partially cationized antigen according to claim 5 or 6 wherein the cationization is effected by coupling the agent to the antigen through an amide bond.

SMART & BIGGAR
OTTAWA, CANADA

PATENT AGENTS



20 FEB. 1996

1338078 557550

~~43~~

ABSTRACT OF THE DISCLOSURE

1

5

10

15

20

25

30

35

A method for preparing an antigenic protein-
containing substance by partially cationizing a native
protein-containing substance to an isoelectric point
ranging from about 6.5 to about 9.5. The partially
cationized substance exhibits increased antigenicity as
compared to the native protein-containing substance and
is useful in mammalian immunization and desensitization
treatments by oral or parenteral administration.